Heart Failure Flashcards
(105 cards)
1
Q
VEHFT-1
A
1st RCT with survival endpoint (improved survival with Hydralazine/ISDN)
2
Q
VEHFT-2
A
FIRST study to demonstrate difference between ACE-I vs Hydralazine/ISDN (Enalapril superior to hydralazine/ISDN for survival); showed difference between vasodilators and ACE-I
3
Q
PRAISE-4
A
- Amlodipine vs placebo (Amlodipine = placebo for survival)
- 1st to show safety of CCB in CHF
4
Q
CONSENSUS-1 (1987)
A
Compared Enalapril vs placebo on top of digoxin + diuretic in NYHA IV (Enalapril superior to placebo for survival)
5
Q
SOLVD
A
Enalapril vs placebo in NYHA II/III : (Enalapril superior to placebo for survival)
6
Q
SOLVD-P
A
Enalapril vs placebo in NYHA I/II (Enalapril superior to placebo)
7
Q
SAVE
A
Captopril vs placebo in post-MI pxs with LV dysfunction (Captopril superior to placebo for survival and CHF onset), FIRST trial to demonstrate remodeling hypothesis
8
Q
AIRE
A
Ramipril vs placebo in HF after MI (improved survival with Ramipril), confirmed results of SAVE
9
Q
MDC
A
Metoprolol vs placebo in NYHA II/III (Metoprolol equal with placebo in terms of survival but showed improved clinical status)
FIRST multicentre clinical trial to assess beta blocker
10
Q
CIBIS-II
A
Bisoprolol vs placebo in NYHA III/IV (Bisoprolol showed reduced mortality)
11
Q
CIBIS III
A
Outcomes did not vary when either ACEi or beta blocker was initiated first
12
Q
MERIT
A
Metoprolol CR/XL with ACE-I (significant reduction in mortality with combination) ; further strengthened the role of of beta blocker in HF
13
Q
COPERNICUS
A
Carvedilol vs placebo on top of standard medical tx, showed reduced CV death and hospitalization
14
Q
SENIORS
A
Nebivolol vs placebo in pxs >=70y/o (no difference in all-cause mortality but showed safety for use in elderly)
15
Q
ELITE
A
looked at the role of ARB in HF. Compared Losartan vs Captopril- found similar results but study was not designed as a superiority study, hence ACE-I is still the drug of choice
16
Q
VAL-Heft
A
Valsartan vs placebo on top of ACE-I (showed added benefit in reducing hospitalization in HF)
17
Q
A-Heft
A
ISDN + hydralazine
18
Q
CHARM-ADDED
A
Candesartan on top of standard medical tx (showed added benefit of ARB on top of ACE-I + BB in hospitalization and mortality)
19
Q
VALIANT
A
Valsartan was noninferior to captopril on all-cause mortality
20
Q
RALES
A
Spironolactone on top of ACE-I, diuretic, digoxin in NYHA III/IV. Showed reduced overall mortality, hospitalization, and progressive HF. Established the role of aldosterone blocker in severe HF
21
Q
EPHESUS
A
Eplerenone on top of standard tx (showed reduced overall CV mortality and hospitalization for CV events)
22
Q
EMPHASIS-HF
A
Eplerenone on top of standard tx for HF with mild symptoms (showed improved CV mortality and hospitalization for HF)
23
Q
SHIFT
A
Ivabradine vs placebo on top of standard tx for pxs with EF <35%. Showed reduced CV death and hospitalizion
24
Q
PARADIGM-HF
A
role of angiotensin receptor-neprilysin inhibitor (ARNI) vs Enalapril for pxs with EF <=35%, NYHA Class II-IV. showed reductions in all-cause mortality, CV mortality, and HF hospitalizations with use of ARNI (Sacubitril/valsartan). Not routinely recommended starting HefRef pxs on ARNIs in pxs with NYHA class II or III who are tolerating ACE-I or ARB, but may be used as a replacement to further reduce mortality
25
PARAMOUNT
ARNI vs Valsartan alone. Double blind RCT in pxs with NYHA Class II/III with EF >45%. Showed improved NYHA functional class with ARNI versus valsartan alone
26
TOPCAT
MRAs shown to improve measures of diastolic function and exercise capacity in HFpEF patients
27
CHAMPION
showed that modifying treatment based on data obtained from implantable hemodynamic monitors (IHMs) will lower HF events in HFpEF pts
28
EVEREST
NYHA Class III/IV hospitalized for worsening HF showed that oral tolvaptan in addition to standard tx improved many, but not all signs and symptoms of HF, without adverse events. But no effect in all cause mortality or composite of cardiovascular death or hospitalization for HF with long term tx
29
I-PRESERVE
no differences and in meaningful endpoints in hfpef patients treated with Irbesartan
30
RELAX
Sildenafil, no improvement in functional capacity, quality of life, or other clincial and surrogate parameters
31
RELAX-AHF
Serelaxin vs placebo, relaxin improved dyspnea, reduced signs of congestion, with less early worsening of HF
32
TRUE-AHF
Ularitide: no improvement over clinical outcomes at 6 mos, associated with higher rate of hypotension and worsening of serum creatinine
33
ALDO-DHF
Spironolactone improved echocardiographic indices of diastolic dysfunction but failed to improve exercise capacity, symptoms, or QOL measures
34
NEAT-HFpEF
ISMN did not improve QOL or submaximal exercise capacity, and decreased overall activity levels in treated patients
35
PARAGON-HF
LCZ696 (ARB with endopeptidase inhibitor) shown to reduce circulating natriuretic peptides and reduce left atrial size to a greater extent than Valsartan alone in patients with HFpEF
36
CARRESS-HF
UF vs stepped pharmacologic care: worsening in creatinine in UF group, more adverse events in UF group including kidney failure, bleeding complications and IV catheter related complications
37
ASCEND-HF
Nesiritide+placebo on top of standard care:clinically insiginificant benefit on dyspnea, increased rates of hypotension
38
REVIVE II
reduced arrhythmias and improved survival with Levosimendan compared to placebo and dobutamine
39
SURVIVE
Levosimendan vs dobutamine – Levosimendan did not reduce all-cause mortality or any secondary clinical outcomes
40
PROTECT
Rolofylline (Selective A1 adenosine receptor antagonist)
41
COSMIC-HF
Omecamtiv mecarbil
42
ASTRONAUT
Aliskiren (direct renin inhibitor) – no significant difference in cardiovascular death or hospitalization at 6 or 12 months
43
OVERTURE
Omapatrilat+neutral endopeptidase inhibitor: this drug did not favorably influence the primary outcome measure of the combined risk of death or hospitalization for HF
44
CORONA & GISSI-HF
low dose Rosuvastatin in pts with HFrEF demonstrated no improvement in aggregrate clinical outcomes
45
WARCEF
full-dose ASA or INR-controlled warfarein – no significant difference in the primary outcome; a reduced risk of ischemic stroke with warfarin was offset by an increased risk of major hemorrhage
46
CARE-HF
first study to demonstrate a reduction in all-cause-mortality with CRT placement in patients with HFrEF on optimal therapy
47
PEP-HF
Perindopril in Elderly People with Chronic Heart Failure
48
3CPO
NIV with cpap or nippv was associated with greater improvement in patient-reported dyspnea, HR, acidosis, and hypercapnea after 1 hour of therapy, although it was not associated with a 7-day mortality benefit or a decreased need for intubation
49
ESCAPE
Use of pulmonary artery catheter (PAC) did not significantly affect the days alive and out of hospital during the first 6 months
50
DOSE
initial dose of 2.5x the OPD dose of diuretics should be considered for patients receiving chronic oral diuretic therapy, with underlying renal dysfunction, or with severe overload
51
ALARM-HF
diuretics + vasodilators had significantly better in-hospital survival than patients treated with diuretics alone in patients with AHF
52
VMAC
decompensated CHF and dyspnea randomized to placebo, nitroglycerin and nesiritide, pts receiving nesiritide had a significantly greater decrease in PCWP
53
ROSE-AHF
Nesiritide had no beneficial effect on urine output or cystatin C or on any of the other secondary endpoints reflective; low dose dopamine did not increase urine volume
54
CASINO
significantly increased mortality with dobutamine compared to placebo
55
DAD-HF
suggested that low dose furosemide + dopamine resulted in comparable urine output and dyspnea relief, but improved renal function profile and potassium homeostasis, compared to high dose furosemide
56
DAD-HF II
no beneficial effect of the addition of low dose dopamine to furosemide
57
OPTIME-CHF
milrinone or placebo-no difference in the primary endpoint of days hospitalized for cardiovascular causes with 60 days, but significant increases in sustained hypotension and new atrial arrhythmias were noted in the milrinone-treated patients
58
SOAP II
dopamine or NE with a non-statistical difference increase in mortality with dopamine associated with a significant increase in arrhythmic events; subgroup analysis including the 280 patients with cardiogenic shock, NE had improved survival compared to dopamine
59
UNLOAD
Patients receiving ultrafiltration demonstrated a greater reduction in body weight at 48 hours, but no improvements in dyspnea or renal function; Intriguingly, there was a reduction in postdischarge events at 90 days with ultrafiltration, although the number of events was small.
60
CARRESS
randomized 188 patients with AHF, WRF, and persistent congestion to a strategy of stepped pharmacologic care (IV diuretics dosed by investigator to maintain urine output of 3 to 5 L/day plus IV vasodilators or inotropes if needed to achieve target urine output) or ultrafiltration (fluid removal rate, 200 mL/hr; UF resulted in similar weight loss but resulted in an increase in creatinine levels
61
AVOID-HF
(Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure) there were trends suggesting longer time to first HF event and fewer HF and cardiovascular events in the adjustable ultrafiltration group compared to those randomized to adjustable IV loop diuretics. There was no difference in renal function, but more patients assigned to ultrafiltration experienced adverse events
62
SMAC-HF
HSS (150 mL 3% normal saline [NS]) plus furosemide (250-mg IV bolus twice daily) and sodium restriction to 120 mmol/day versus furosemide (250-mg IV bolus twice daily) and sodium restriction to 80 mmol/day; There was a shorter LOS, increased creatinine clearance at discharge, reduced readmission rate, and improved survival for patients in the HSS group.
63
VERITAS
addition of IV tezosentan to standard therapy did not improve symptoms nor decrease worsening HF or mortality at 7 days after randomization
64
BLAST-AHF
TRV027 conferred no benefit over placebo at any dose with regard to the primary composite endpoint or any of the individual components, although there were no significant safety issues.
65
SOCRATES-Reduced study
vericiguat did not significantly improve log-transformed NT-proBNP concentrations compared to placebo, but there was a suggestion of a dose-response effect
66
ATOMIC-AHF
IV omecamtiv mecarbil did not meet the primary endpoint of dyspnea improvement compared to the pooled placebo
67
TACTICS
Tolvaptan vs placebo - Tolvaptan resulted in greater weight loss and net fluid loss vs placebo but likely to experience worsening renal function
68
HORIZON-HF
addition of istaroxime to standard therapy lowered PCWP and heart rate and increased SBP
69
RED-HF
Darboietin alfa in heart failure
70
RAPID-CHF
FIRST RCT of ultrafilitration for ADHF
71
ELITE-II
losartan was not associated with improved survival in elderly HF patients compared to captopril but was significantly better tolerated
72
HEAAL
high-dose losartan was not associated with significant reduction in the primary endpoint of patients with HF compared to low-dose losartan, but was associated with a reduction in hospitalization
73
BEST
Bucindolol
74
CAPRICORN
Carvedilol
75
BEAT
Bucindolol
76
COMET
Carvedilol was associated with a significant 33% reduction in all-cause mortality compared with Metoprolol tartrate
77
BEAUTIFUL
10,000 patients with coronary heart disease and EF <40% were randomized to Ivabradine, this trial did not meet its primary endpoint of reducing CV death, MI, or HF hospitalization, Ivabradine was well tolerated in this patient population
78
ALOFT
aliskiren was shown to decrease significantly NT-proBNP in urinary aldosterone
79
ATMOSPHERE
same result with ASTRONAUT, clinical trials failed to improve outcomes in HFrEF patients, and renin inhibitors such as aliskiren are not presently recommended as an alternative to an ACEI or ARB or in combination with ACEIs
80
RADIANCE and PROVED
Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme and the Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin (PROVED), provided strong support for clinical benefit from digoxin
81
DIG
digoxin had a neutral effect on the primary endpoint of mortality, digoxin reduced hospitalizations
82
GISSI-HF
1g/day of omega 3 PUFA resulted in significant reduction in both all-cause mortality
83
GENETIC-AF
bucindolol vs metoprolol succinate on recurrence of symptomatic atrial fibrillation/atrial flutter in HF patients
84
STICH
CABG did not reduce all cause death
85
ANDROMEDA
Drodenarone - two-fold increased mortality in HF patients
86
HF-action
exercise training did not have a favorable impact on all-cause mortality or HF hospitalization
87
MUSTIC
safety and efficacy of CRT in patients with advanced HF, ventricular dyssynchrony;
FIRST randomized SINGLE-blinded trials of CRT for HF; primary endpoints were exercise tolerance assessed by measurement of peak oxygen consumption (VO2) or the 6-minute hall walk distance (6MHWD) test and quality of life determined using the Minnesota Living with Heart Failure (MLWHF) questionnaire; Secondary endpoints included rehospitalizations and/or drug therapy modifications for worsening HF
88
MIRACLE
FIRST prospective, randomized, DOUBLE-blind, parallel- controlled clinical trial designed to evaluate the benefits of CRT; Primary endpoints were NYHA class, quality of life score (using the MLWHF questionnaire), and 6MHWD. Secondary endpoints included assessments of a composite clinical response, cardiopulmonary exercise performance, cardiac structure and function, a variety of measures of worsening HF, and combined morbidity and mortality
89
MIRACLE ICD
prospective, multicenter, random- ized, double-blind, parallel-controlled clinical trial intended to assess the safety and efficacy of a combined CRT-ICD system in patients with dilated cardiomyopathy
90
CONTAK CD
enrolled 581 symptomatic HF patients with ventricular dyssynchrony and malignant ventricular tachyarrhythmias, who were all candidates for an ICD
91
COMPANION
was a multicenter, prospective RCT designed to compare drug therapy alone to drug therapy combined with CRT in patients with dilated cardiomyopathy, an intraventricular conduction defect (IVCD), NYHA Class III or IV HF, and no indication for a device; Compared to optimal medical therapy alone, the combined endpoint of mortality or HF hospitalization was reduced by 35% for patients receiving CRT and 40% for patients receiving CRT-ICD
92
REVERSE
the first large, randomized, multicenter trial to demonstrate the potential for CRT to slow progression of disease through reverse remodeling in NYHA Class I and II HF patients with ventricular dyssynchrony.
93
MADIT CRT
multicenter RCT designed to address the potential survival and morbidity benefit of CRT in NYHA Class I and II HF patients by assessing the reduction in risk of death and nonfatal HF events; led the FDA to expand the indication for CRT to NYHA Class II or ischemic Class I patients, with LVEF less than 30%, QRS duration longer than 130 milliseconds, and LBBB
94
RAFT
FIRST to show a mortality benefit of combined CRT-ICD over an ICD alone, and a mortality reduction with the addition of CRT in patients in NYHA
95
EchoCRT
CRT in patients with NYHA Class III or IV HF, LVEF of 35% or less, QRS duration less than 130 milliseconds, and echocardiographic evidence of LV dyssynchrony; demonstrated the potential for harm in using CRT in narrow-QRS patients. Thus, CRT is considered contraindicated in these patients.
96
Landmark trials establishing the role of ICD’s as primary prevention of mortality in HF patients (3)
MADIT II
DEFINITE
SCD-HeFT
97
MADIT II
prospectively designed and powered to assess the survival benefit of ICDs in a population of post–myocardial infarction (MI) patients with reduced EF (<30%).
98
DEFINITE
FIRST RCT of primary prevention therapy with an ICD in nonischemic cardiomyopathy patients
99
SCD-HeFT
three-arm trial, comparing treatment with an ICD to amiodarone and placebo; ICD was associated with a statistically significant 23% reduction in all-cause mortality compared to placebo; provides the most robust evidence to date supporting the prophylactic use of an ICD in patients with NYHA Class II and III systolic HF
100
DANISH
prophylactic ICD insertion in pts with symptomatic HF not caused by CAD was not associated with significant lower long-term rate of death from any cause than the usual clinical care
101
ISTIMIR
evaluating MV replacement and repair for severe ischemic MR demonstrated no difference in short- or long-term mortality between patients cohorts
102
PARTNER
demonstrated TAVR to be a safe treatment strategy in high-risk patients LV dysfunction
103
RESTORE
(Reconstructive Endoventricular Surgery Returning Torsion Original Radius Elliptical Shape to the Left Ventricle) multicenter study investigated various techniques for LV reconstruction
104
CUPID 2
delivery of SERCA 2a for the treatment of heart failure
105
CARVEDILOL-US
Carvedilol vs placebo in NYHA II/III
(Carvedilol superior to placebo for morbidity and mortality) However this was not designed as a mortality study
follow-up period was short
